Zoll Medical, a Massachusetts-based manufacturer of medical devices, has acquired assets of CoAxia, a Minnesota-based medical device company that provides catheter-based perfusion augmentation therapies, for an undisclosed amount.

The purchase of CoAxia’s intellectual property aligns with Zoll’s acute critical care portfolio of products, such as temperature management, which may minimise the reperfusion injury following ischemia with the use of balloon catheters.

Besides many patents on cerebral perfusion augmentation, CoAxia’s intellectual property includes other patents related to several vascular procedures.

The primary application for CoAxia’s catheter technology involves redistribution of blood flow from the lower extremities to support the brain function of a patient during ischemia.

"CoAxia’s intellectual property includes other patents related to several vascular procedures."

This technology, traded as NeuroFlo and FloControl, offers potential applications in blood flow redistribution for trauma, cardiac arrest, coronary procedures, surgical blood loss and renal perfusion.

NeuroFlo and FloControl have received regulatory approvals in the US.

The US Food and Drug Administration (FDA) has granted Humanitarian Device Exemption clearance to NeuroFlo for treatment of patients with vasospasm following subarachnoid hemorrhage, while FloControl has been given 510(k) clearance approval for stopping and controlling blood flows in the peripheral vasculature.

Using dual balloons to create temporary partial obstruction in the descending aorta, the blood flow redistribution technology of the NeuroFlo and FloControl causes a redistribution of cardiac output from the lower extremities to the cerebral vasculature without actually raising arterial blood pressure.

Zoll president James Palazzolo said the NeuroFlo technology has the potential to address a large portion of the population who suffer cerebral ischemia, offering a significant benefit to patients and the healthcare system.

"Our task is to continue to develop the significant body of clinical evidence started by CoAxia demonstrating the safety and efficacy of the NeuroFlo catheter and, in the end, do what is necessary for it to be a standard treatment option for hundreds of thousands of stroke patients worldwide," Palazzolo added.

Palazzolo also announced that the company intends to carry out a follow-up to the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke clinical trial in the near future.